Harmony Misses EPS, But WAKIX Sales Surge Past $1B

Forward-Looking Analysis

Wall Street analysts project Harmony Biosciences (HRMY) to report Q2 2026 earnings per share (EPS) of $1.11, a significant increase from the Q1 2026 consensus of $0.76. This upward revision reflects the company's strong preliminary results and reaffirmed full-year 2026 net revenue guidance of over $1 billion. Analysts estimate Q2 revenue to reach approximately $250.77 million, driven by robust WAKIX sales momentum. The consensus rating remains a "Buy" with a price target of $39.86, supported by the company's ability to delay generic competition through legal actions and expanded sales forces. While bears cite risks regarding clinical delays and royalty payments from the Novitium settlement, bulls emphasize the potential for blockbuster status due to strong cash flows and pipeline assets. The company's financial health is bolstered by a trailing P/E ratio of 14.52 and a forward P/E of 10.91, indicating expected earnings growth of 17.27% next year.

Historical Performance Review

Harmony’s 2026Q1 results demonstrated solid commercial execution despite missing EPS estimates. The company reported revenue of $215.39 million, up 16.6% year-over-year, though slightly below the $220.84 million consensus. Net income stood at $32.49 million, with a gross profit of $170.88 million. However, EPS came in at $0.56, missing the $0.76 expectation by $0.21. Despite the earnings miss, the revenue growth and strong gross margins highlighted the commercial viability of WAKIX. The company maintained its full-year guidance, signaling confidence in sustaining this revenue trajectory through the remainder of 2026.

Additional News

Harmony Biosciences has actively strengthened its executive leadership and corporate governance. In April 2026, the company appointed Glenn Reicin as Chief Financial Officer, effective immediately, alongside additions to its Board of Directors, including Ron Philip, to support strategic growth. The company reaffirmed its 2026 net revenue guidance of over $1 billion in WAKIX sales during its Q1 earnings release on May 7, 2026. Commercially, Harmony continues to vigorously protect its intellectual property, filing suit against AET Pharma/Sandoz regarding infringement of its amorphous pitolisant patent. Additionally, the company announced poster presentations at the 2026 SLEEP Annual Meeting and participation in investor conferences, including the Goldman Sachs 47th Annual Global Healthcare Conference in June 2026. These activities underscore Harmony's commitment to advancing its pipeline, including the Phase 3 ARGUS trial data for EPX-100, while maintaining a strong commercial foundation for its core narcolepsy treatments.

Summary & Outlook

Harmony Biosciences exhibits strong financial health, driven by double-digit revenue growth and robust gross margins, despite recent EPS misses. The primary growth catalyst is the continued expansion of WAKIX sales, supported by a confirmed $1 billion+ annual revenue target and effective IP litigation delaying generic entry until 2030. Risks remain regarding clinical trial delays and royalty obligations, but the company’s diversified pipeline and strategic executive appointments mitigate these concerns. With a consensus "Buy" rating and positive cash flow generation, the outlook is cautiously bullish. The upcoming Q2 earnings report will be critical in validating the upward EPS trajectory and confirming the sustainability of revenue momentum into the second half of 2026.